This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Urquiza, M.
Right arrow Articles by Patarroyo, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Urquiza, M.
Right arrow Articles by Patarroyo, M. E.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 2008, p. 3714-3720, Vol. 46, No. 11
0095-1137/08/$08.00+0     doi:10.1128/JCM.00551-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Specificity of L1 Peptides versus Virus-Like Particles for Detection of Human Papillomavirus-Positive Cervical Lesions in Females Attending Engativa Hospital, Bogota, Colombia{triangledown}

Mauricio Urquiza,1,2* Ricardo Sánchez,1,2 Jairo Amaya,2,3 Sandra León,1 Jenny Acosta,1 Manuel A. Patarroyo,1,2 Milena Camargo,1 and Manuel E. Patarroyo1,2

Fundacion Instituto de Inmunologia de Colombia,1 Universidad Nacional de Colombia,2 Hospital de Engativa, Bogota, Colombia3

Received 22 March 2008/ Returned for modification 14 June 2008/ Accepted 6 September 2008

A serological test for the detection of human papillomavirus (HPV) infection in females at risk of developing cervical cancer could be based on conserved L1 peptides with low levels of antigenicity specifically recognized by antibodies from patients with cervical lesions infected with high-risk HPV (HR-HPV) types. The aim was to assess the ability of L1 peptides 18283, 18294, and 18301 compared with the ability of virus-like particles (VLPs) to identify these infections in females. A total of 391 HPV-infected female volunteers were interviewed, and peripheral blood and cervical cells were obtained for detection of anti-HPV antibodies and HPV DNA; all of the patients had a Pap smear test; 287 patients were referred for colposcopy or biopsy, according to gynecological criteria. The level of agreement, as determined by the use of the Lin coefficient (rho value), showed that 75 to 83% of females with HR-HPV DNA-positive cervical lesions had antibodies that recognized VLPs and peptide 18283, 18294, or 18301, while 15 to 23% of the HPV DNA-negative females with a normal cytology had antibodies that recognized these three peptides and 45% had antibodies that recognized VLPs. The rate of agreement between peptides and VLPs for antibody detection was higher for patients with HPV DNA-positive cervical lesions. Peptides 18283, 18294, and 18301 showed similar sensitivities for the detection of HR-HPV DNA-positive cervical lesions and were more specific than VLPs. Peptide 18301 might be detecting protective antibodies in HPV DNA-negative females with atypical squamous cells of undetermined significance. These peptides could be useful for the design of a serology test for the detection of HR-HPV infection in females with cervical lesions and at risk of cervical cancer.

* Corresponding author. Mailing address: Virology, Fundacion Instituto de Inmunologia de Colombia, Carrera 50, #26-00, Bogota 020304, Colombia. Phone: 57-1-4815269. Fax: 57-1-3244672, ext. 108. E-mail: mauricio_urquiza{at}fidic.org.co

{triangledown} Published ahead of print on 17 September 2008.

Journal of Clinical Microbiology, November 2008, p. 3714-3720, Vol. 46, No. 11
0095-1137/08/$08.00+0     doi:10.1128/JCM.00551-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»